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Abstract. There is a wide interest in biomarkers that capture the burden of detrimental factors as these accumulate with
the passage of time, i.e., increasing age. Telomere length has received considerable attention as such a marker, because it
is easily quantified and it may aid in disentangling the etiology of dementia or serve as predictive marker. We determined
the association of telomere length with risk of Alzheimer’s disease and all-cause dementia in a population-based setting.
Within the Rotterdam Study, we performed quantitative PCR to measure mean leukocyte telomere length in blood. We
determined the association of telomere length with risk of Alzheimer’s disease until 2016, using Cox regression models. Of
1,961 participants (mean age 71.4 ± 9.3 years, 57.1% women) with a median follow-up of 8.3 years, 237 individuals were
diagnosed with Alzheimer’s disease. We found a U-shaped association between telomere length and risk of Alzheimer’s
disease: compared to the middle tertile the adjusted hazard ratio was 1.59 (95% confidence interval (CI), 1.13–2.23) for the
lowest tertile and 1.47 (1.03–2.10) for the highest tertile. Results were similarly U-shaped but slightly attenuated for all-cause
dementia. In conclusion, shorter and longer telomere length are both associated with an increased risk of Alzheimer’s disease
in the general population.
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INTRODUCTION
Dementia is a devastating disease affecting mil-
lions of people worldwide. While advances over
the past decades have unraveled several pathologi-
cal mechanisms underlying dementia, chronological
age remains the most important predictor for demen-
tia onset [1]. There is, therefore, a wide interest in
biomarkers that capture the burden of detrimental fac-
tors as these accumulate with the passage of time,
i.e., increasing age. Such markers, that are preferably
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easily quantified, may aid in disentangling the eti-
ology of dementia or ultimately serve as predictive
markers. Against this background, telomere length
has received considerable attention [2].
Telomeres are repetitive base pair sequences at the
end of chromosomes and facilitate complete chromo-
some replication [3]. Since the replication machinery
is unable to copy the ends of DNA, telomeres will
shorten with each cell division. A change in telom-
ere length resulting in shortened telomeres induces a
DNA damage response that leads to a growth arrest
during which cells attempt to repair the damage and
if DNA damage is irreparable, replicative senescence
or cell death is triggered [4]. Very short telomeres
have relatively low cancer risk (due to cell senescence
blocking cell division), but could be associated with
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increased DNA damage [5]. Given the tight link with
cell death, short telomere length has been linked to
poorer survival [6, 7] and other age-related diseases,
including dementia as has been shown in a recent
meta-analysis [8]. Conversely, there is evidence that
over-elongated telomeres represent pathological cell
function with decreased DNA repair and increased
cancer risk [9], which has also been shown in human
embryonic stem cells [10], while “normally” long
telomeres are protective, including against DNA
damage. With respect to Alzheimer’s disease, there
is also evidence suggesting an increased risk of mild
cognitive impairment related to both short and long
telomeres [11]. Additionally, hippocampal cells of
Alzheimer’s disease brains are shown to have longer
telomeres compared to control samples [12]. It is,
thus, conceivable that not only shorter but also longer
telomere length may be detrimental for dementia
risk. However, the temporal relation between longer
telomere length and dementia has so far not been
investigated. Therefore, the aim of this study is to
investigate the association between blood cell telom-
ere length and risk of Alzheimer’s disease and to
explore non-linearity within this association.
METHODS
Design and study population
This study was embedded within the Rotterdam
Study, a prospective population-based cohort study
among middle-aged and elderly individuals in the
Netherlands. Three cohorts were established in 1990,
2000, and 2006, respectively. From each cohort, par-
ticipants were invited every 4–5 years to undergo
follow-up examinations. We refer the reader to the
Rotterdam Study methods paper for further informa-
tion [13]. For this study, a total of 2,140 participants
were randomly selected from the first (1990–2004,
N = 7983) and third cohorts (2006–2008, N = 3932)
for telomere length measurement. From these par-
ticipants, 1,961 were dementia-free at baseline visit
and had complete telomere length data available at
baseline (Fig. 1).
The Rotterdam Study has been approved by the
Medical Ethics Committee of the Erasmus MC and
by the Ministry of Health, Welfare and Sport of the
Netherlands, implementing the Wet Bevolkingson-
derzoek: ERGO (Population Studies Act: Rotterdam
Study). All participants provided written informed
consent to participate in the study and to obtain infor-
mation from their treating physicians.
Assessment of telomere length
Blood for all samples was collected in EDTA
tubes and stored at –20◦C until DNA isolation.
DNA isolation was done with a method based
on salting out, with different lysis buffers for the
different cohorts. The OD260/280 and OD260/230
for both isolation methods did not differ significantly
between the two cohorts. The average OD260/280
ratio was 1.90 with a standard deviation of 0.10
and the average OD260/230 ratio was 1.61 with a
standard deviation of 0.46 in a random sample of
168. Telomere length was measured using a qPCR
assay based on the method described by Cawthon
[14] with minor modifications. The SDS software of
the 7900HT qPCR machine is not able to analyze
the qPCR data produced at two different temperature
points. Therefore, we chose the singleplex assay for
this study. For each sample, the telomere and 36B4
assay were run in separate wells but in the same 384
wells PCR plate. Each reaction contained 5 ng DNA,
1M of each of the telomere primers (tel1b-forward:
GGTTTGTTTGGGTTTGGGTTTGGGTTTGGGT
TTGGGTT, tel2b-reverse: GGCTTGCCTTACCC
TTACCCTTACCCTTACCCTTACCCT) or 250 nM
of the 34B4 primers (36B4u-forward: CAGCAA
GTGGGAAGGTGTAATCC, 36B4d-reverse: CCC
ATTCTATCATCAACGGGTACAA) and 1× Quan-
tifast SYBR green PCR Mastermix (Qiagen). The
reactions for both assays were performed in duplicate
for each sample in a 7900HT machine (Applied
Biosystems). Ct values and PCR efficiencies were
calculated per plate using the MINER algorithm
[15]. Duplicate Ct values that had a coefficient
of variance (CV) of more than 1% were excluded
from further analysis. Using the average Ct value
per sample and the average PCR efficiency per
plate the samples were quantified using the formula
Q = 1/(1 + PCR eff)∧Ct. The relative telomere length
was calculated by dividing the Q of the telomere
assay by the Q of the 34B4 assay. To validate the
assay, 96 random samples were run twice and the
CV of that experiment was 4.5%. Telomere length
was measured in 37 batches.
Ascertainment of incident dementia
Baseline and follow-up ascertainment methods for
dementia have previously been described in detail
[16]. In brief, participants were screened for dementia
at baseline and subsequent center visits. In addition,
the entire cohort was continuously under surveil-
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Fig. 1. Flowchart of study population.
lance for dementia through electronic linkage of the
study database with medical records. A consensus
panel led by a consultant neurologist established
the final diagnosis according to standard criteria
for dementia (DSM-III-R) and Alzheimer’s disease
(NINCDS–ADRDA). Within this period, participants
were censored at date of dementia diagnosis, death,
loss to follow-up, or 1 January 2016, whichever came
first.
APOE genotyping
APOE genotype was determined using polymerase
chain reaction on coded DNA samples in the base-
line cohort [17] and with a bi-allelic Tacqman assay
(rs7412 and rs429358) in the extensions of the Rotter-
dam Study [13]. APOE 4 carrier status was defined
carriers versus non-carriers of the 4 allele.
Other covariates
Potential confounding factors were chosen on the
basis of previous literature [16, 18]. All covariates
were measured at baseline. Educational attainment
was categorized as low (primary education or lower
vocational education), intermediate (secondary edu-
cation or intermediate vocational education), and
high educational level (higher vocational education
or university). Smoking habits were categorized as
current, former and never smoking. Body mass index
was calculated as weight in kilograms per height in
meters squared. Blood pressure was measured twice
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at the right brachial artery with the participant in
sitting position, out of which the mean was used.
Hypertension was defined as a resting blood pressure
exceeding 140/90 mmHg or the use of blood pres-
sure lowering medication. Hypercholesterolemia was
defined as a total cholesterol of ≥6.2 mmol/L or the
use of serum lipid-reducing agents. White blood cell
counts were assessed with a Coulter AcT diff2 Hema-
tology Analyzer at the research center in Ommoord.
On 14 February 2005, a new device of the same brand
and type was installed. Prevalent stroke was assessed
at baseline during interview and we verified these
data with medical records. After study entry, we con-
tinuously monitored participants after enrollment for
incident stroke through linkage of the study database
with files from general practitioners. Files of nursing
home physicians and files from general practitioners
of participants who moved out of the district were also
checked. We obtained additional information from
hospital records. When potential strokes were found,
they were reviewed by research physicians and veri-
fied by an experienced neurologist.
Statistical analysis
Missing covariate data (maximum 2.2%) were
imputed using 5-fold multiple imputation based on
determinant, outcome, and included covariates. In
all models, we adjusted for age continuously, sex
and center visit since data was randomly selected
from 4 center visits from 2 subcohorts. We addi-
tionally adjusted for educational attainment, APOE
4 carrier status, smoking, body mass index, hyper-
tension, hypercholesterolemia, and white blood cell
count in a second model, all at time of blood draw.
We first explored linearity of telomere length with
Alzheimer’s disease and dementia risk by entering
T/S ratio as restricted cubic spline with 3 knots in
Cox regression models. In order to further quantify
potential non-linearity, T/S ratio was subsequently
divided into tertiles, defined as T/S ratio of 0.31–0.87,
0.87–1.02, and 1.02–1.79, respectively. To provide a
parsimonious description of the telomere-dementia
relationship and facilitate communication of the
results, we assessed the association between telomere
length in tertiles, comparing lowest and highest ter-
tiles that represent the shortest and longest telomere
lengths, respectively, to the middle tertile, with risk
of Alzheimer’s disease and dementia. We repeated
the analysis for Alzheimer’s disease, by adjusting not
only for age at blood draw, but also for age at demen-
tia diagnosis or date of last follow-up as an attempt to
assess survival bias. We further verified that age was
robustly controlled for by comparing results across
models using five different ways of age-adjustment.
These included no adjustment for age, entering age
and age2 in the model, entering age as cubic splines,
repeating the analyses with age rather than follow-
up time as the time scale and finally regressing the
effect of age out of T/S ratio before creating T/S
ratio tertiles. We performed an additional adjust-
ment for plate number to rule out batch effects. The
proportional hazards assumption was assessed using
Schoenfeld residuals. We next repeated the analyses
for Alzheimer’s disease, but excluding all participants
with prior clinical stroke at baseline and censoring for
incident clinical stroke during follow-up using Cox
models.
We also assessed interaction by age, sex, educa-
tion, or APOE 4 carrier status by stratification and
testing for multiplicative interaction by including the
product of the interacting factor and T/S ratio con-
tinuously as a restricted cubic spline (4 knots) to take
into account the non-linear relationship between T/S
ratio and Alzheimer’s disease. We stratified for age
by 3 groups, namely 45–65 years, 65–85 years, and
85–105 years.
All analyses were performed using RStudio ver-
sion 0.99.903 (R version 3.4.3 [19], RStudio, Inc.,
Boston, MA). We used the following R packages for
our analyses: mice, survival, rms, and scales.
RESULTS
Baseline characteristics of the study population
are presented in Table 1. The mean age of the par-
ticipants was 71.4 ± 9.3 years with 57.1% women.
During a median follow-up of 7.3 (interquartile range
4.9–11.7) years (26,025 person-years), 305 individu-
als were diagnosed with dementia of whom 237 were
Alzheimer’s disease.
There was evidence of non-linearity in the asso-
ciation between telomere length and Alzheimer’s
disease (Supplementary Figure 1). Compared to
the middle tertile of telomere length, we found an
adjusted hazard ratio (aHR) of 1.59; 95% confidence
interval (CI), 1.13–2.23 for lowest tertile of telomere
length and 1.47; 95%CI, 1.03–2.10 for highest ter-
tile of telomere length for Alzheimer’s disease, with
similar but lower estimates for dementia (Table 2).
When additionally adjusting for age at dementia diag-
nosis or date of last follow-up, we found an aHR of
1.52; 95%CI, 1.07–2.18 for lowest tertile of telom-
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Table 1
Baseline characteristics of the dementia-free study population
Characteristics Dementia-free cohort
(N = 1961)
Women 1120 (57.1%)
Age, y 71.4 ± 9.3
Cohort
First 1543 (78.7%)
Third 418 (21.3%)
Education
Primary education 366 (18.9%)
Lower/intermediate general education 806 (41.5%)
Intermediate vocational education 535 (27.6%)
Higher vocational education 233 (12.0%)
Apolipoprotein E 4 carriership
Non-carrier (2/2, 2/3, or 3/3) 1411 (72.0%)
Carrier (4/4, 3/4, or 2/4) 550 (28.0%)
Smoking
Current 405 (21.1%)
Former 921 (48.0%)
Never 592 (30.9%)
Body mass index, kg/m2 27.2 ± 4.1
Hypertension 700 (36.5%)
Hypercholesterolemia 949 (48.8%)
White blood cell count 6.9 ± 2.3
Telomere length, T/S ratio 0.95 ± 0.18
N, number of participants included in study. Data presented as
mean (standard deviation) for continuous variables and number
(percentages) for categorical variables. T/S ratio is relative telom-
ere to single copy gene ratio. Data represent original data without
imputed values. Number of missing values are 43 (2.2%) for smok-
ing, 21 (1.1%) for education, 27 (1.4%) for hypertension, 17 (0.9%)
for hypercholesterolemia, 29 (1.5%) for body mass index, and 157
(8.0%) for white blood cell count. Data for apolipoprotein E 4
carriership was complete.
ere length and 1.75; 95%CI, 1.21–2.54 for highest
tertile of telomere length for Alzheimer’s disease,
compared to the middle tertile. Other approaches
of age-adjustment yielded similar results (Table 3).
There were no batch effects. The proportional haz-
ards assumption was met for all models. Results
were slightly attenuated but remained U-shaped after
excluding participants with prior clinical stroke at
baseline and censoring for incident clinical stroke:
compared to middle tertile aHR: 1.44, 1.02–2.05 for
lowest tertile of telomere length and aHR 1.30, 95%
CI 0.90–1.89 for highest tertile of telomere length.
In the stratified analyses, the association between
shorter and longer telomeres and Alzheimer’s dis-
ease was stronger in APOE 4 carriers compared to
non-carriers (Fig. 2) with the multiplicative interac-
tion term yielding p = 0.087. Stratification for age,
sex, and education did not provide different risk esti-
mates (p-values for interaction: p = 0.554, p = 0.600,
and p = 0.123, respectively).
DISCUSSION
In this study, shorter as well as longer telomere
length were significantly associated with increased
risk of dementia, specifically Alzheimer’s disease.
Thus far, focus in the dementia field has been
on shorter telomere length with studies finding
observationally as well as genetically associations
between shorter telomere length and increased risk
of Alzheimer’s disease [20–23]. Moreover, a recent
meta-analysis which included 13 primary studies
demonstrated significantly shorter telomere length in
860 Alzheimer’s disease patients compared to 2,022
controls [8]. Interestingly, we found that in addition
to shorter telomere length also longer telomere length
was associated with an increased dementia risk. This
finding is in line with previous studies [24, 25], partic-
ularly the study by Roberts and others [11] showing
that short and long telomeres increase risk of amnes-
tic mild cognitive impairment. Yet, we emphasize
that further replication is necessary to confirm the
robustness of our findings with dementia.
An explanation for our observations with longer
telomere length might be survival bias, where pre-
sumably participants with the longest telomere length
live long enough to develop dementia. This is, how-
ever, less likely since associations remained after
additional adjustment for age at dementia diagnosis
or end of follow-up. Alternatively, it is plausible that
Table 2
Telomere length and the risk of Alzheimer’s disease and all-cause dementia
n/N Alzheimer’s disease n/N All-Cause dementia
Model I HR, Model II HR, Model I HR, Model II HR,
95% CI 95% CI 95% CI 95% CI
Telomere length
Tertile 1 (T/S ratio 0.31–0.87) 106/654 1.54, 1.10–2.15 1.59, 1.13–2.23 129/654 1.25, 0.94–1.66 1.27, 0.96–1.70
Tertile 2 (T/S ratio 0.87–1.02) 54/654 1 (reference) 1 (reference) 80/654 1 (reference) 1 (reference)
Tertile 3 (T/S ratio 1.02–1.79) 77/653 1.41, 0.99–2.00 1.47, 1.03–2.10 96/653 1.19, 0.88–1.60 1.25, 0.92–1.69
n, number of cases; N, number of persons at risk; HR, hazard ratio; CI, confidence interval; T/S ratio, relative telomere to single copy gene
ratio. Cox regression model I: Adjusted for age, sex, and visit. Cox regression model II: Adjusted for age, sex, visit, education, APOE 4
carrier status, smoking, body mass index, hypertension, hypercholesterolemia, and white blood cell count.
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Table 3
Association between telomere length and Alzheimer’s disease using different modes of age adjustment
Adjustment Alzheimer’s disease
No age Age + age2 Cubic splines Age as Regressing out the effect
adjustment for age† time-scale of age of T/S ratio∗
n/N HR, 95% CI HR, 95% CI HR, 95% CI HR, 95% CI HR, 95% CI
Telomere length
Tertile 1 (shortest) 106/654 2.08, 1.49–2.91 1.64, 1.17–2.30 1.64, 1.17–2.30 1.63, 1.16–2.29 1.33, 0.96–1.86
Tertile 2 (middle) 54/654 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Tertile 3 (longest) 77/653 1.25, 0.88–1.77 1.45, 1.01–2.06 1.45, 1.02–2.06 1.44, 1.01–2.06 1.22, 0.87–1.69
n, number of cases; N, number of persons at risk; HR, hazard ratio; CI, confidence interval; T/S ratio, relative telomere to single copy gene
ratio. †Cubic splines with 3 knots, similar results for higher degree polynomials. Models adjusted for age, sex, visit, education, APOE 4
carrier status, smoking, body mass index, hypertension, hypercholesterolemia, and white blood cell count. ∗Regressing the effect of age out
of T/S ratio before creating T/S ratio tertiles; no additional adjustment for age in the model; similar results for additionally regressing out
the effect of sex.
Fig. 2. A visual representation of telomere length and the risk
of Alzheimer’s disease stratified by APOE 4 carriership with
restricted cubic splines in Cox model II, adjusted for age, sex,
study visit, education, APOE 4 carrier status, smoking, body mass
index, hypertension, hypercholesterolemia and white blood cell
count. Number of Alzheimer’s disease cases in APOE 4 carrier
group: 102 with 550 persons at risk; number of cases in the APOE
4 non-carrier group: 135 with 1411 persons at risk.
a disturbed equilibrium of telomere length toward
either direction is harmful. Indeed, over-elongated
telomeres become fragile and accumulate DNA dam-
age, as has been shown by an experimental study in
human embryonic stem cells, and very tight control of
telomere length homeostasis is regulated by not only
telomerase-dependent elongation, but also by telom-
ere trimming events [10]. Another study has shown
that telomerase RNA component (TERC) knockout
mice with Alzheimer’s disease, which present with
telomere shortening, slows down the progression of
A pathology, showing a more protective effect of
short telomere length [26], thereby supporting a detri-
mental effect of longer telomere length. The potential
biological link between over-elongated telomeres and
higher Alzheimer’s disease risk remains to be further
elucidated. In contrast with longer telomere length,
more is known about the potential biological link
between shorter telomeres and increased Alzheimer’s
disease risk. Neurons lacking telomerase reverse tran-
scriptase (TERT) in knockout mice and thus have
shorter telomeres, display an increased production of
oxidative species and an increase in cellular oxidative
damage in response to tau, demonstrating a harmful
effect of shorter telomeres [27]. Therefore, telom-
erase may play different roles in the tau and amyloid
pathology via multiple mechanisms [28]. In addition,
microglial cellular senescence may also be an impor-
tant mechanism in the development of Alzheimer’s
disease, which is suggested to be exacerbated by
the presence of amyloid [29, 30]. Further studies are
warranted to differentiate between a true biological
association and survival bias. If a true biological asso-
ciation exists between longer telomere length and risk
of dementia, telomerase therapies, which have been
successful in mice [31, 32], would need further fine-
tuning to prevent over-elongation of telomere length.
Interestingly, we found stronger effects for
Alzheimer’s disease compared to all-cause dementia.
This might be reflective of the fact that Alzheimer’s
disease is a more homogeneous entity than all-cause
dementia, which includes a plethora of etiologies.
Certain limitations must be taken into account.
First, we measured telomere length in leukocytes in
blood. This may not be representative of telomere
length in the brain, in particular glial cells. How-
ever, a previous study has shown a direct correlation
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between telomeres measured from peripheral blood
and cerebellum [33], suggesting blood cell telomere
length to be a valid measurement. Another limi-
tation of measuring telomere length in leukocytes
is that lymphocytes are the only peripheral blood
cells expressing telomerase activity and therefore are
able to maintain telomere length despite prolifera-
tion, while granulocytes lack the ability for further
cell division [34]. Therefore, it is possible that the
older individuals without dementia have a greater
proportion of lymphocytes (fewer granulocytes) [35],
and thus longer telomere length. Unfortunately, we
were not able to adjust for the percentage of lympho-
cytes to overcome this issue, since this data was not
available for all center visits. Another issue is that
leukocytes divide peripherally in response to various
stresses (e.g., infection) and the telomere length may
therefore change unexpectedly. Also, research cen-
ters may vary in reliability in measuring leukocyte
telomere length. Second, we measure mean telom-
ere length, while cell senescence is suggested to be
related to and modulated by the shortest telomere
length per cell [36]. Third, the external validity of
the results may be limited due to the single center
nature of this study. Finally, despite using different
approaches yielding similar results, the effect of age
may not have been taken into account entirely. Nev-
ertheless, given the link of older age with shorter
telomere length and older age with Alzheimer’s dis-
ease, controlling for age would if anything strengthen
the association between longer telomere length and
risk of Alzheimer’s disease.
In conclusion, shorter and longer telomere length
are associated with an increased risk of Alzheimer’s
disease in a sample of elders in The Netherlands. Fur-
ther studies are warranted to confirm our findings,
in particular studies with imaging or fluid biomark-
ers available for dementia diagnosis, and to unravel
any underlying biological pathway from possible
methodological bias.
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